Edition:
United States

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

5.98USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$5.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,548
52-wk High
$11.65
52-wk Low
$2.65

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $58.64
Shares Outstanding(Mil.): 9.73
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): 4.21 108.51 32.45
EPS (TTM): 1.43 -- --
ROI: 25.67 1.61 12.63
ROE: 27.67 0.35 14.80

BRIEF-Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations

* CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

May 10 2018

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

Mar 22 2018

Earnings vs. Estimates